About Inovio Pharmaceuticals, Inc. - Common Stock (INO)
Inovio Pharmaceuticals is a biotechnology company focused on developing innovative therapies and vaccines for the treatment of serious diseases, particularly cancers and infectious diseases. Utilizing its proprietary DNA medicines platform, Inovio is engaged in creating synthetic DNA-based therapies that aim to trigger an immune response in the body to fight off disease. The company is dedicated to advancing its product candidates through various phases of clinical trials, and it collaborates with various organizations and institutions to enhance its research and development efforts, ultimately striving to address unmet medical needs and improve patient outcomes. Read More
The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
INOVIO reported Q2 2025 results with $0.0 revenue and a $0.61 EPS loss, meeting estimates. Shares fell 4.7% post-earnings amid pipeline uncertainty. Key focus remains on DNA medicine candidates like INO-3107.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Let's have a look at what is happening on the US markets before the opening bell on Thursday. Below you can find the top gainers and losers in today's pre-market session.
As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
LONDON and PHILADELPHIA, July 01, 2025 (GLOBE NEWSWIRE) -- Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces the appointment of David Liebowitz, M.D., Ph.D. as Chief Medical Officer (CMO) and Yulii Bogatyrenko as an advisor in business development. Dr. Liebowitz will lead the Company’s clinical strategy and execution as it continues to advance its pipeline of targeted cancer therapies and Mr. Bogatyrenko will add additional strength to the Group’s business development strategy.
